Y-Biologics, Inc
338840
企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
Y-Biologics, Inc is a company that secures various antibody drug candidates based on one of the best antibody discovery platform technologies in South Korea, and either independently develops antibody therapeutics or jointly develops advanced biopharmaceuticals by combining its technology with partner companies' platform technologies. The company currently has a total of five pipelines under independent development, consisting of various immuno-oncology new drug candidates: (1) Acriksolimab (YBL-006), an immune checkpoint inhibitor targeting PD-1; (2) YBL-011, an immune checkpoint inhibitor targeting LAG-3; (3) AR062, an antibody therapeutic that targets CD39 to regulate the tumor microenvironment; (4) TGFβ Selectrap® (AR148), an antibody analog that targets TGFβ 1&3 to regulate the tumor microenvironment; and (5) AR092, a T cell engager bispecific antibody therapeutic.
代表理事
박영우, 박범찬(각자대표)
成立日期
2007年12月31日
法人类型
韩国创业板
行业分类
Research and experimental development on medical sciences and pharmacy
法人注册号
16011-0235641
营业执照号
314-81-95083
电话号码
042-867-9971
传真号码
042-867-9970
公司地址
대전광역시 유성구 테크로 4로 17, 비715호
产品与服务
评论